Alnylam Pharmaceuticals(ALNY)

CAMBRIDGE, MAPharmaceutical3 H-1B visas (FY2023)

Focus: Alnylam is a public specialty pharma company pioneering RNAi therapeutics across gene therapy and neurology, with four marketed products generating $1.8B in FY 2025 revenue.

Gene Therapy Neurology

Profile data last refreshed 23h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$250M

Open Jobs

About Alnylam Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Alnylam Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$1.8B

Key Products

AMVUTTRA

Transthyretin Amyloidosis with Cardiomyopathy

$67M Part D

Peak

Help build intelligence for Alnylam Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

CIDP treatment patterns and outcomes

Chronic Inflammatory Demyelinating Polyneuropathy

N/A

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Re

Transthyretin Amyloidosis With Cardiomyopathy

N/A

Clinical Trials (1)

NCT07358078DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

N/A

TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positiv

Transthyretin Amyloidosis

N/A

Clinical Trials (1)

NCT03237494TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects

N/A

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac

Familial Amyloidotic Cardiomyopathy (FAC)

N/A

Clinical Trials (1)

NCT02252653DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

N/A

DemonsTTRate ATTR-CM Registry

Transthyretin Amyloidosis With Cardiomyopathy

N/A

ATTR Prevalence and Prediction Study

Transthyretin Amyloidosis

N/A

TRAMmoniTTR TTR Screening and Monitoring Study

Transthyretin Amyloidosis

N/A

Patisiran Pregnancy Surveillance Program

Hereditary Transthyretin-mediated (hATTR) Amyloidosis

N/A

Patisiran ATTRv Effectiveness Study

Hereditary Transthyretin-mediated (ATTRv) Amyloidosis

N/A

99mTc-pyrophosphate Scintigraphy

Transthyretin Amyloidosis

N/A

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

N/A

Clinical Trials (1)

NCT04883905ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

N/A

INSIGHT-AHP Acute Hepatic Porphyria Prevalence Study

Acute Hepatic Porphyria

N/A

ALECT2 Disease Natural History Study

Leukocyte Chemotactic Factor 2 Amyloidosis

N/A

ConTTRibute ATTR Amyloidosis Registry

Transthyretin-Mediated Amyloidosis

N/A

TTR Amyloidosis Biomarker Study

Hereditary Amyloidosis, Transthyretin-Related

N/A

Natural History of Acute Hepatic Porphyria

Acute Hepatic Porphyria

N/A

Givosiran (Acute Hepatic Porphyria registry)

Acute Hepatic Porphyria

N/A

INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients Wit

Acute Hepatic Porphyria

N/A

Clinical Trials (1)

NCT03547297INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

N/A

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

N/A

Clinical Trials (1)

NCT02240784EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

N/A

ALN-GO1 (Primary Hyperoxaluria registry)

Primary Hyperoxaluria Type 1

N/A

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

Amyloidosis

N/A

Clinical Trials (1)

NCT03774784A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

N/A

Standard of Care

Hereditary Amyloidosis, Transthyretin-Related

N/A

Clinical Trials (3)

NCT06272487Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Phase 2

NCT05103332Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis

Transthyretin-Mediated Amyloidosis

N/A

Clinical Trials (1)

NCT04561518ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

N/A

DISCOVERY Cardiac Amyloidosis Prevalence Study

Familial Amyloidotic Cardiomyopathy (FAC)

N/A

No intervention. Retrospective observation only.

Chronic Inflammatory Demyelinating Polyneuropathy

N/A

Clinical Trials (1)

NCT05940922RWE-based Treatment Patterns and Outcomes in CIDP

N/A

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 1

N/A

Clinical Trials (1)

NCT04982393BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

N/A

ALN-TTRSC04

Transthyretin-Mediated Amyloidosis

Phase 1

Clinical Trials (1)

NCT05661916A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Phase 1

ALN-TTR02

TTR-mediated Amyloidosis

Phase 1

Clinical Trials (5)

NCT01960348APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Phase 3

NCT02510261The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

ALN-4915

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT07535606A Study to Evaluate ALN-4915 in Adult Healthy Volunteers

Phase 1

ALN-AGT01 RVR

Hypertension

Phase 1

ALN-PCSSC

Hypercholesterolemia

Phase 1

Clinical Trials (1)

NCT02314442A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Phase 1

ALN-HTT02

Huntington's Disease

Phase 1

Clinical Trials (1)

NCT06585449A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Phase 1

ALN-BCAT

Advanced Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT06600321A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Phase 1

ALN-5288

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT07214727A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Phase 1

ALN-HBV

Chronic Hepatitis B

Phase 1

Clinical Trials (1)

NCT02826018A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

Phase 1

ATTR Algorithm Identification Study

Transthyretin Amyloidosis

Phase 1

Computer algorithm for ATTR

Transthyretin Amyloidosis

Phase 1

Clinical Trials (1)

NCT04569903Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Phase 1

ALN-TTRSC02

Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

Phase 1

Clinical Trials (1)

NCT02797847A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Phase 1

ALN-HSD

Nonalcoholic Steatohepatitis (NASH)

Phase 1

Clinical Trials (1)

NCT04565717A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Phase 1

ALN-PCS02

Elevated LDL-Cholesterol (LDL-C)

Phase 1

Clinical Trials (1)

NCT01437059Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

Phase 1

ALN-4285

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT07295717A Study to Evaluate ALN-4285 in Adult Healthy Volunteers

Phase 1

ALN-AAT

Antitrypsin Deficiency Liver Disease

Phase 1

Clinical Trials (1)

NCT02503683A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase 1

ALN-VSP02

Solid Tumors

Phase 1

Clinical Trials (2)

NCT00882180Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

Phase 1

NCT01158079Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

ALN-TTR01

Transthyretin Mediated Amyloidosis (ATTR)

Phase 1

Clinical Trials (1)

NCT01148953Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

Phase 1

ALN-AAT02

ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase 1/2

Clinical Trials (1)

NCT03767829A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase 1/2

ALN-6400

Hereditary Hemorrhagic Telangiectasia (HHT)

Phase 1/2

Clinical Trials (1)

NCT06659640A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Phase 1/2

ALN-KHK

Type 2 Diabetes Mellitus (T2DM)

Phase 1/2

Clinical Trials (1)

NCT05761301A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Phase 1/2

ALN-CC5

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1/2

Clinical Trials (1)

NCT02352493A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

Phase 1/2

ALN-XDH

Gout

Phase 1/2

Clinical Trials (1)

NCT05256810A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout

Phase 1/2

ALN-2232

Obesity

Phase 1/2

Clinical Trials (1)

NCT07463846A Study to Evaluate ALN-2232 in Participants With Obesity

Phase 1/2

Alnylam Pharmaceuticals(ALNY)

About Alnylam Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (4)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Recent News · Alnylam Pharmaceuticals(9)

Open Jobs (0)

Financials (FY2025)

Visa Sponsorship

Private Funding (SEC Form D)